CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice

AIM: There is limited information concerning the effects of canagliflozin (CANA), a sodium‐glucose co‐transporter 2 inhibitor (SGLT2i) in a real‐world clinical setting in Canada. CanCARE is a 12‐month, prospective, observational analysis to demonstrate the effectiveness and safety of CANA in usual c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Obes Metab
Main Authors: Woo, Vincent, Bell, Alan, Clement, Maureen, Noronha, Luis, Tsoukas, Michael A., Camacho, Fernando, Traina, Shana, Georgijev, Natasha, Culham, Matthew D., Rose, Jennifer B., Rapattoni, Wally, Bajaj, Harpreet S.
Formato: Artigo
Idioma:Inglês
Publicado em: Blackwell Publishing Ltd 2018
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6667918/
https://ncbi.nlm.nih.gov/pubmed/30393961
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13573
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados